This innovative strategy addresses several critical limitations of current therapies by offering (1): catalytic, long-lasting effects that enable less frequent dosing (2); elimination of both enzymatic and scaffolding functions of STING; and (3) broad potential applicability across autoimmune disorders, fibrotic conditions, and neurodegenerative diseases. The gene discussed is STING1; the disease is neurodegenerative disease.